EUVIMEDEUVIMED entdecken
Crossref

Preclinical Characterization of [68Ga]Ga/[177Lu]Lu-PSNT-AB: A Dual-Targeted Agent against PSMA and NTSR1 for Prostate Cancer Theranostics

Quan Xie, Ying Peng, Qingzhu Liu iD, Jiawen Qin, Jing Li, Xinru Li, Ling Qiu, Jianguo Lin iD

Journal of Medicinal Chemistry · 12.11.2026 · 69 (21) · 26414-26424

DOI: 10.1021/acs.jmedchem.6c02236 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 29.10.2026. Verfasst von Quan Xie und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Health Commission Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Med…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Glutamate Carboxypeptidase II, Receptors, Neurotensin, Antigens, Surface. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Jiangsu Provincial Medical Key Discipline Laboratory, Jiangsu Commission of Health, Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate-specific membrane antigen (PSMA) is a key biomarker for prostate cancer (PCa), while neurotensin receptor 1 (NTSR1) is positive in PSMA-negative PCa lesions. For comprehensive diagnosis and therapy of PCa, we synthesized dual-targeted PSNT-AB (combining PSMA-targeted EuK, NTSR1-targeted NT-20.3, albumin-binding 4-p-tolylbutyric acid and DOTA moieties) and prepared [68Ga]Ga/[177Lu]Lu-PSNT-AB. [68Ga]Ga-PSNT-AB possessed high affinity for PSMA-positive LNCaP and moderate affinity for NTSR1-positive PC-3 cells. Probes accumulated time-dependently in relevant cells, and [177Lu]Lu-PSNT-AB exerted potent cytotoxicity. Pharmacokinetics revealed prolonged blood half-lives for both probes. PET imaging revealed persistent [68Ga]Ga-PSNT-AB uptake in LNCaP, 22Rv1 and PC-3 tumors (10.29 ± 0.25% ID/g, 6.61 ± 0.30% ID/g, 3.74 ± 0.12% ID/g at 3 h post-injection). SPECT/CT showed sustained [177Lu]Lu-PSNT-AB retention in LNCaP tumors for at least 24 h. These results demonstrated that [68Ga]Ga/[177Lu]Lu-PSNT-AB are promising dual-targeted probes for PCa diagnosis and therapy, offering a potential strategy for comprehensive and effective precision management of PCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsGlutamate Carboxypeptidase IIReceptors, NeurotensinAntigens, SurfaceRadiopharmaceuticalsMaleHumansGallium RadioisotopesLutetiumAnimalsTheranostic NanomedicineCell Line, TumorRadioisotopesMice

Stichwörter der Autor:innen

NTSR1PET imagingPSMAalbumin bindingprostate cancertheranostics

Substanzen

Gallium RadioisotopesGlutamate Carboxypeptidase IIReceptors, NeurotensinLutetiumAntigens, SurfaceFOLH1 protein, humanLutetium-177neurotensin type 1 receptorGallium-68Radioisotopes

Autor:innen und Institutionen

  • National Health Commission Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi214063, China.
  • Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing211166, China.

ORCID-Profile: Qingzhu Liu, Jianguo Lin

Förderung

  • Jiangsu Provincial Medical Key Discipline Laboratory
  • Jiangsu Commission of Health
  • Natural Science Foundation of Jiangsu Province

Zitieren

APA

Xie, Q., Peng, Y., Liu, Q., Qin, J., Li, J., Li, X., Qiu, L., & Lin, J. (2026). Preclinical Characterization of [68Ga]Ga/[177Lu]Lu-PSNT-AB: A Dual-Targeted Agent against PSMA and NTSR1 for Prostate Cancer Theranostics. Journal of Medicinal Chemistry, 69(21), 26414-26424. https://doi.org/10.1021/acs.jmedchem.6c02236

Vancouver

Xie Q, Peng Y, Liu Q, Qin J, Li J, Li X, et al. Preclinical Characterization of [68Ga]Ga/[177Lu]Lu-PSNT-AB: A Dual-Targeted Agent against PSMA and NTSR1 for Prostate Cancer Theranostics. Journal of Medicinal Chemistry. 2026;69(21):26414-26424. doi:10.1021/acs.jmedchem.6c02236

BibTeX
@article{Xie2026,
  author = {Xie, Quan and Peng, Ying and Liu, Qingzhu and Qin, Jiawen and Li, Jing and Li, Xinru and Qiu, Ling and Lin, Jianguo},
  title = {Preclinical Characterization of [68Ga]Ga/[177Lu]Lu-PSNT-AB: A Dual-Targeted Agent against PSMA and NTSR1 for Prostate Cancer Theranostics},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {21},
  pages = {26414--26424},
  doi = {10.1021/acs.jmedchem.6c02236}
}
Kostenlos starten →